Ken Griffin Compass Pathways PLC Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	N/A	20,100 Added 16.13%	144,700 $1.24 Million
Q2 2024 Aug 14, 2024	BUY	N/A	78,400 Added 169.7%	124,600 $1.06 Million
Q1 2024 May 15, 2024	BUY	N/A	5,300 Added 12.96%	46,200 $394,000
Q4 2023 Feb 14, 2024	BUY	N/A	19,100 Added 87.61%	40,900 $349,000
Q3 2023 Nov 14, 2023	BUY	N/A	1,500 Added 7.39%	21,800 $186,000
Q2 2023 Aug 14, 2023	SELL	$7.79 - $10.69 $74,784 - $102,624	-9,600 Reduced 32.11%	20,300 $173,000
Q1 2023 May 15, 2023	BUY	$7.32 - $10.85 $30,012 - $44,485	4,100 Added 15.89%	29,900 $296,000
Q4 2022 Feb 14, 2023	SELL	$7.84 - $11.68 $228,928 - $341,056	-29,200 Reduced 53.09%	25,800 $207,000
Q3 2022 Nov 14, 2022	SELL	$10.73 - $20.07 $113,738 - $212,742	-10,600 Reduced 16.16%	55,000 $590,000

151

33.6M

536K

582K

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.